The Subtype Identity of Testicular Cancer Cells Determines Their Immunostimulatory Activity in a Coculture Model.

NTERA-2 T cell TCam-2 cytokines inflammation monocyte non-seminoma seminoma testicular germ cell cancer tumor microenvironment

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
05 May 2023
Historique:
received: 21 03 2023
revised: 20 04 2023
accepted: 02 05 2023
medline: 13 5 2023
pubmed: 13 5 2023
entrez: 13 5 2023
Statut: epublish

Résumé

Testicular germ cell cancer (TGCC) is subdivided into several subtypes. While seminomatous germ cell tumors (SGCT) are characterized by an intensive infiltration of immune cells which constitute a pro-inflammatory tumor micromilieu (TME), immune cells in non-seminomatous germ cell tumors (NSGCT) are differently composed and less abundant. Previously, we have shown that the seminomatous cell line TCam-2 promotes T cell and monocyte activation in a coculture model, resulting in mutual interactions between both cell types. Here we set out to compare this feature of TCam-2 cells with the non-seminomatous cell line NTERA-2. Peripheral blood T cells or monocytes cocultured with NTERA-2 cells failed to secrete relevant amounts of pro-inflammatory cytokines, and significantly downregulated the expression of genes encoding activation markers and effector molecules. In contrast, immune cells cocultured with TCam-2 cells produced IL-2, IL-6 and TNFα, and strongly upregulated the expression of multiple pro-inflammatory genes. Furthermore, the expression of genes involved in proliferation, stemness and subtype specification remained unaltered in NTERA-2 cells during coculture with T cells or monocytes, indicating the absence of mutual interactions. Collectively, our findings uncover fundamental differences between SGCT and NSGCT in their capability to generate a pro-inflammatory TME, which possibly impacts the clinical features and prognosis of both TGCC subtypes.

Identifiants

pubmed: 37174085
pii: cancers15092619
doi: 10.3390/cancers15092619
pmc: PMC10177190
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : Deutsche Forschungsgemeinschaft
ID : Scholarship
Organisme : Deutsche Forschungsgemeinschaft
ID : RE 1631/17-1

Références

Int J Cancer. 2020 Mar 15;146(6):1592-1605
pubmed: 31583686
Cell Tissue Res. 2008 Feb;331(2):529-38
pubmed: 18008088
Int J Androl. 2007 Aug;30(4):350-65
pubmed: 17705808
Oncoimmunology. 2017 Mar 20;6(4):e1305535
pubmed: 28507813
Cancers (Basel). 2022 Aug 19;14(16):
pubmed: 36011006
Curr Med Chem. 2018;25(36):4785-4806
pubmed: 28707587
Genes Chromosomes Cancer. 2008 Mar;47(3):185-96
pubmed: 18050305
Crit Rev Oncol Hematol. 2007 Dec;64(3):182-97
pubmed: 17644403
Br J Cancer. 2022 Apr;126(6):937-947
pubmed: 35022523
Eur Urol. 2015 Dec;68(6):1054-68
pubmed: 26297604
Am J Surg Pathol. 2006 Jul;30(7):858-65
pubmed: 16819328
Pigment Cell Melanoma Res. 2015 Sep;28(5):490-500
pubmed: 25818762
Semin Immunol. 2014 Feb;26(1):38-47
pubmed: 24602448
Immunol Invest. 1995 May;24(4):607-18
pubmed: 7622197
Nat Rev Cancer. 2005 Mar;5(3):210-22
pubmed: 15738984
Int J Mol Sci. 2021 Jun 29;22(13):
pubmed: 34209703
Cells. 2022 Mar 04;11(5):
pubmed: 35269507
Oncogene. 2003 Mar 27;22(12):1880-91
pubmed: 12660824
Andrology. 2017 Jul;5(4):763-770
pubmed: 28544640
Hum Reprod. 2016 Oct;31(10):2192-202
pubmed: 27609978
J Reprod Immunol. 2013 Dec;100(2):135-45
pubmed: 24290033
Oncology (Williston Park). 2002 Feb;16(2):217-26, 229; discussion 230-2
pubmed: 11866137
J Immunother Cancer. 2017 Mar 21;5:28
pubmed: 28331617
Mech Dev. 2005 Sep;122(9):1034-42
pubmed: 16023837
J Proteome Res. 2019 Apr 5;18(4):1819-1826
pubmed: 30835130
Urology. 2013 Feb;81(2):464.e1-9
pubmed: 23374840
Rev Sci Tech. 1998 Apr;17(1):84-94
pubmed: 9638802
Eur J Immunol. 2017 Jul;47(7):1232-1242
pubmed: 28555838
Oncotarget. 2016 Jul 26;7(30):47095-47110
pubmed: 27283990
Histopathology. 2021 Mar;78(4):593-606
pubmed: 32970854
J Hematol Oncol. 2021 Mar 19;14(1):45
pubmed: 33741032
Hum Cell. 2020 Oct;33(4):930-937
pubmed: 32507979
Dis Markers. 2019 Sep 3;2019:8298524
pubmed: 31565104
Cancer Biol Ther. 2010 Sep 15;10(6):529-36
pubmed: 20855948
BMC Clin Pathol. 2012 Oct 15;12:19
pubmed: 23066729
Eur J Cancer. 2020 Jun;132:127-135
pubmed: 32361383
PLoS One. 2014 Jan 03;9(1):e83585
pubmed: 24404135
Genes Chromosomes Cancer. 2012 Jul;51(7):717-26
pubmed: 22489004
Int J Cancer. 1999 Dec 10;83(6):815-22
pubmed: 10597201

Auteurs

Fabian A Gayer (FA)

Institute for Cellular and Molecular Immunology, University Medical Center Göttingen, 37073 Göttingen, Germany.
Clinic of Urology, University Medical Center Göttingen, 37075 Göttingen, Germany.

Miriam Henkel (M)

Institute for Cellular and Molecular Immunology, University Medical Center Göttingen, 37073 Göttingen, Germany.

Juliane Luft (J)

Institute for Cellular and Molecular Immunology, University Medical Center Göttingen, 37073 Göttingen, Germany.

Sybille D Reichardt (SD)

Institute for Cellular and Molecular Immunology, University Medical Center Göttingen, 37073 Göttingen, Germany.

Alexander Fichtner (A)

Institute of Pathology, University Medical Center Göttingen, 37075 Göttingen, Germany.

Tobias J Legler (TJ)

Department of Transfusion Medicine, University Medical Center Göttingen, 37075 Göttingen, Germany.

Holger M Reichardt (HM)

Institute for Cellular and Molecular Immunology, University Medical Center Göttingen, 37073 Göttingen, Germany.

Classifications MeSH